

ASRS 43rd Annual Scientific Meeting | July 30-August 2, 2025 | Long Beach, California

			Wednesday, July 30		
6:45 AM	7:45 AM		Continental Breakfast		
7:45 AM	11:00 AM	195	Retina Surgical Summit (NO CME OR LIVESTREAM)		
			Team Europe: Carl Claes, MD; Carlos Mateo, MD; Marco Mura, MD; Zofia A Nawrocka, MD, PhD; Tom H. Williamson, MD, MBChB, FRCS, FRCOphth	Moderator: Stanislao Rizzo, MD	
			Team of the Americas Martin Charles, MD; Alexandre Grandinetti, MD, PhD; Gabriela Lopezcarasa Hernandez, MD; Virgilio Morales-Canton, MD; Carmen R. Negrin-Martin, MD; Cynthia X. Qian, MD	Moderator: Maria H. Berrocal, MD	
			Team Asia Hussain Ahmad Khaqan, MD; Marie Joan Loy, MD, DPBO, FPAO; Manish Nagpal, MD, FRCS (UK), FASRS; Gavin Tan, MBBS, FRCSEd, FAMS, PhD; Taku Wakabayashi, MD, PhD; Wei-Chi Wu MD, PhD	Moderator: Yusuke Oshima, MD, PhD	
11:00 AM	11:30 AM	30	Lunch Break		
11:30 AM	12:30 PM	60	Retina Battle	Moderators: Kourous A Rezaei, MD; David R Chow, MD, FRCS(C)	
			Team 1: Lejla Vajzovic, MD, FASRS; Flavio A. Rezende, MD, PhD; Yoshihiro Yonekawa, MD, FASRS		
			Team 2: Aleksandra V. Rachitskaya, MD, FASRS; Matteo Forlini, MD; Jorge A. Fortun, MD		
			Team 3: Audina M. Berrocal, MD, FASRS; John W. Kitchens, MD; Joel Pearlman, MD, PhD		
12:30 PM	1:30 PM	60	Retinaws (NO RECORDING)	Moderator: Kourous A Rezaei, MD.	
			Panelists: Maria H Berrocal, MD; Geoffrey G Emerson, MD, PhD, FASRS; Avni P Finn, MD, MBA, FASRS; Sunir J Garg, MD, FACS, FASRS; J Michael Jumper, MD, FASRS; Adrienne W Scott, MD, FASRS; Gaurav K Shah, MD; Christina Y Weng, MD, MBA, FASRS; Charlie C Wykoff, MD, FASRS		
1:30 PM	3:00 PM	90	Surgical Case Conference	Moderators:	
			Presenters: Sulaiman M Al Sulaiman, MD; Carmen Baumann, MD, PhD, FEBO; Barton Blackorby, MD; Subhendu Boral, MBBS, MD(AIIMS), DNB; Lawrence Chan, MD; Jonathan Chang, MD, FASRS; Geoffrey Emerson, MD, PhD, FASRS; Mallika Goyal, MD; Srinivas Joshi, MD, FASRS; Talia Kaden, MD; Aditya Kelkar, MS, FRCS, FASRS,FRCOphth; Mark McAllister, MD; Sandra Montezuma, MD; Matthew Ohr, MD; Geovanni Rios, MD; Sami Uwaydat, MD; Christina Weng, MD, MBA, FASRS; Zhaotian Zhang, MD	Moderators: Dean Elliott, MD; Prithvi Mruthyunjaya, MD, MHS; Lejla Vajzovic, MD, FASRS	
3:00 PM	3:30 PM	30	Break		
3:30 PM	5:00 PM	90	Medical Case Conference		
			Presenters: Nazanin Barzideh, MD, FASRS; Audina M Berrocal, MD FASRS; Andrew Farag, MD; Hong-Uyen Hua, MD; Harsh H Jain, MBBS, DNB; George Jiao, MD; Colin A McCannel, MD; Mohamed R Mohamed, MD; Spencer M Moore, MD, PhD; Kareem Moussa, MD; Robert A Sisk, MD, FACS, FASRS; Bradley T Smith, MD, FASRS; Mudit Tyagi, MS, FASRS; Lejla Vajzovic, MD, FASRS; Rui Wang, MD; Yoshihiro Yonekawa, MD, FASRS; Yuxi Zheng, MD; James L Zimmerman, MD	Moderators: Sruthi Arepalli, MD; Srinivas R Sadda, MD; David Sarraf, MD	
6:00 PM	10:00 PM		Opening Reception: Ballast Point		
			Thursday, July 31		
6:45 AM	7:45 AM		Experience Lab (Fellows & Residents)		
6:45 AM	7:45 AM		Fellowship Directors Breakfast		
8:00 AM	8:05 AM	5	Opening Comments	Gaurav K Shah, MD	
8:05 AM	8:10 AM	5	State of Retina	J Michael Jumper, MD, FASRS	
8:10 AM	8:45 AM	35	Retinal Detachment Symposium 1		
		3	The Feasibility and Outcomes of Vitrectomy in the Office-Based Operation Room	Taku Wakabayashi, MD, PhD	8:10 AM
		3	The Use of Incorrect Intraocular Gas Tamponades During Vitreoretinal Surgery	Gaurav K Shah, MD	8:13 AM
		3	Lincoff vs Artificial Intelligence: A Reappraisal of Lincoff's Rules for Finding the Retinal Tear	John T Thompson, MD	8:16 AM
		9	Discussion		8:19 AM
			Minimally Invasive Suprachoroidal Buckling Using a Novel Injector: Preclinical Evaluation in Human Cadaver Eyes	Gareth D Mercer, MD, PhD	8:28 AM
		3	Preoperative OCT Biomarkers of Outer Retinal Alterations in Rhegmatogenous Retinal Detachment: Predictors of Postoperative Visual Outcomes	Eoi Jong EJ Seo, MD, PhD	8:31 AM
		3	Evaluation of Macular Perfusion Post Rhegmatogenous Retinal Detachment Surgery Using Optical Coherence Tomography Angiography: A Systematic Review and Meta-Analysis	Muhammad Amer R Awan, MD, FRCSEd, FRCOphth, FRCS Glasgow, FACS, FASRS	8:34 AM
		8	Discussion		8:37 AM
8:45 AM	9:20 AM	35	Retinal Detachment Symposium 2		
		3	Risk of Retinal Detachment in Fellow Eye With Lattice Degeneration After Primary Rhegmatogenous Retinal Detachment	Chase A Ludwig, MD, MS	8:45 AM

			Risk of New Retinal Tear or Detachment After Cataract Surgery in Patients With Previously Treated Phakic Retinal Tears	Basil K Williams, MD	8:48 AM
		3	Predictors of Primary Rhegmatogenous Retinal Detachment Surgical Revision	Ahmed F Shakarchi, MD, MPH	8:51 AM
		8	Discussion		8:54 AM
			Lyophilized Amniotic Membrane Patches Are a Safe and Effective Treatment for Rhegmatogenous Lesions in Combined Tractional and Rhegmatogenous Retinal Detachment	Angel Garcia, MD	9:02 AM
		3	Predictors of Primary Anatomic Reattachment With Pneumatic Retinopexy for Rhegmatogenous Retinal Detachment	Aurora Pecaku, MD	9:05 AM
			Comparison of Retinal Detachment Repair Outcomes Using 20% Sulphhexafluoride (SF6) vs Air Tamponade in Pars Plana Vitrectomy Surgery With or Without Scleral Buckle	Trent Chiang, MD, MS	9:08 AM
		3			9:11 AM
		9	Discussion		9:11 AM
9:20 AM	9:41 AM	21	Case-Based Panel Discussion: Surgery	J. Michael Jumper, MD, FASRS	9:20 AM
9:41 AM	10:01 AM	20	Invited Talk: What Every Retina Doctor Needs to Know About Neuro-ophthalmology	Andrew G. Lee, MD	9:41 AM
10:01 AM	10:41 AM	40	Break		10:01 AM
10:41 AM	10:51 AM	10	Invited Talk: Diabetic Retinopathy: Underappreciated or Overemphasized Managements in 2025	Neil M Bressler MD	10:41 AM
10:51 AM	11:31 AM	40	Diabetic Retinopathy Symposium 1		
			Volumetric Analysis of Hard Exudates on Optical Coherence Tomography: Biomarker Results of Faricimab vs Aflibercept From Phase 3 YOSEMITE/RHINE	Murtaza K Adam, MD	10:51 AM
		3	Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the United States	Andres Emanuelli, MD	10:54 AM
			Update on Faricimab for DME: New Clinical Features of Eyes in the RHONE-X Long-Term Extension Study	Veeral S Sheth, MD, MBA, FASRS, FACS	10:57 AM
		3			10:57 AM
		9	Discussion		11:00 AM
			Comparability of Diabetic Retinopathy Severity Evaluation on Gold Standard vs Ultra-Widefield Images in YOSEMITE/RHINE Phase 3 Studies	Barbara A Blodi, MD	11:09 AM
		3	VERONA: End-of-Study Results From a Phase 2 Trial of EYP-1901 (Vorolanib Intravitreal Insert) vs Aflibercept for Diabetic Macular Edema	Yasha S Modi, MD	11:12 AM
			Early Insights From Real-World Use of Aflibercept 8 mg Among Eyes With Diabetic Macular Edema Switching From Other Anti-VEGF Agents	Michael Javaheri, MD	11:15 AM
		3	Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study	Eric Schneider, MD	11:18 AM
					11:21 AM
		10	Discussion		11:21 AM
11:31 AM	12:11 PM	40	Diabetic Retinopathy Symposium 2		
			Interim Results From the SPECTRA Phase 2a Clinical Trial Evaluating Intravitreal 4D-150 in Adults With Diabetic Macular Edema	David Almeida, MD, MBA, PhD, DABO, FRCSC, FASRS	11:31 AM
		3	Impact of PDS in Study Eyes vs Anti-VEGF Injections in Fellow Eyes in Pagoda Trial Patients With Bilateral Diabetic Macular Edema (DME)	Jordan M Graff, MD, FACS	11:34 AM
			A Phase I Study to Evaluate the Tie2 Agonist RO7446603, Alone or in Combination With Aflibercept or Faricimab, in Diabetic Macular Edema	Jeremiah Brown, MD, MS, FASRS	11:37 AM
		3	Longitudinal Quantitative Ultra-Widefield Retinal Leakage Assessment in Diabetic Retinopathy Following a Single Axitinib Hydrogel (OTX-TKI) in the HELIOS Trial	Katherine E Talcott, MD	11:40 AM
			Suprachoroidal Avoralstat, a Plasma Kallikrein Inhibitor, Stops Vascular Leakage in a Well-Established Rabbit Model	Dilsher S Dhoot, MD	11:43 AM
		3			11:43 AM
			Efficacy and Safety Outcomes over 12 weeks with OCS-01 Eye Drops in DME From DIAMOND-Stage 1 trial: Focus on Subgroup by Prior Treatment Status	Baruch D Kuppermann, MD, PhD, FASRS	11:46 AM
		3	Senolytic Candidate UBX1325 for Diabetic Macular Edema: The BEHOLD Phase 2 and ASPIRE Phase 2b Trials	Dante Pieramici, MD	11:49 AM
					11:52 AM
		19	Discussion		11:52 AM
12:11 PM	12:32 PM	21	Case-Based Panel Discussion: Diabetic Retinopathy	Charles C Wyckoff, MD, PhD, FASRS	12:11 PM
12:32 PM	1:47 PM	75	General Lunch + WinR Lunch		12:32 PM
1:47 PM	2:02 PM	15	Business Meeting		1:47 PM
2:02 PM	2:12 PM	10	Invited Talk: Future Treatments for Dry Macular Degeneration	David S Boyer, MD	2:02 PM
2:12 PM	2:52 PM	40	Dry AMD Symposium 1		
			Baseline Characteristics Associated With Geographic Atrophy Progression in the OAKS and DERBY Trials	Srinivas R Sadda, MD	2:12 PM
		3	Early vs Delayed Pegcetacoplan Treatment for GA Secondary to AMD: 48-Month Results From OAKS, DERBY, and GALE Open-Label Extension	Roger A Goldberg, MD, MBA	2:15 PM
		3			2:15 PM

			Clinical Utility of the Fellow Eye in Patients With Bilateral GA Due to AMD: Long-Term Data from the 3 Pegcetacoplan Clinical Program	Diana V Do, MD, FASRS	2:18 PM
		10	Discussion		2:21 PM
		3	Complement Inhibition Treatment for Geographic Atrophy in Eyes With Exudative AMD	Josh O Wallsh, MD	2:31 PM
		3	A Descriptive Analysis of Patients Who Received Pegcetacoplan and Anti-VEGF for the Treatment of 3 Geographic Atrophy and Neovascular AMD	Nimesh A Patel, MD, FASRS	2:34 PM
		3	Safety Profiles of Combined Anticomplement and Anti-VEGF Intravitreal Therapies for Age-Related Macular 3 Degeneration From Real-World Data	Edward H Wood, MD, FASRS	2:37 PM
		3	Progression of Geographic Atrophy in Patients Receiving Both Anti-VEGF and Pegcetacoplan Injections	Ash Pirouz, MD	2:40 PM
		9	Discussion		2:43 PM
2:52 PM	3:32 PM	40	Dry AMD Symposium 2		
		3	The 12-Month Safety Results of the PRIMAvera Clinical Trial	Lisa C Olmos de Koo, MD, MBA	2:52 PM
		3	ARCHER II, a Phase 3 Randomized Clinical Trial of ANX007 in Patients With Dry AMD and GA: Study Design and 3 Rationale Informed by Outcomes From ARCHER	David A Eichenbaum, MD, FASRS	2:55 PM
		3	LIGHTSITE IIIB: A Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy of 3 Photobiomodulation in Dry Age-Related Macular Degeneration	David S Boyer, MD	2:58 PM
		9	Discussion		3:01 PM
		3	Impact of AREDS Oral Micronutrient Supplementation on Geographic Atrophy Progression: Insights From the 3 Phase 3 OAKS and DERBY Trials	Paul Hahn, MD, PhD, FASRS	3:10 PM
		3	New AREDS Data Analyses on Whether AREDS Patients Should Have Routine Genetic Testing	Stephen R Kaufman, MD	3:13 PM
		3	Genotype Prediction From Retinal Fundus Images Using Deep Learning in Eyes With Age-Related Macular 3 Degeneration	Glenn C Yiu, MD, PhD	3:16 PM
		3	Novel Handheld Device for Remote Monitoring of Non-neovascular Age-Related Macular Degeneration and 3 Clinical Validation of Usability and Comfort	Yannis M Paulus, MD	3:19 PM
		10	Discussion		3:22 PM
3:32 PM	4:12 PM	40	Break		3:32 PM
4:12 PM	4:42 PM	30	Macular Pucker - Epiretinal Membrane & Macular Holes Symposium 1		
		3	First Applications of Digital Surgery in Ophthalmology	Stanislao Rizzo, MD	4:12 PM
		3	Double Agents of the Vitreous: An En Face OCT Study of Hyalocytes Post Vitrectomy	Richard B Rosen, MD, DSc(Hon), FACS, FASRS, FARVO	4:15 PM
		3	The Role of Preoperative En Face OCT to Identify Non-internal Limiting Membrane Peeling Candidates for 3 Macular Hole Surgery	Kotaro Tsuboi, MD	4:18 PM
		3	Large Preretinal Human Amniotic Membrane Graft for Chronic or Persistent Macular Holes	Aristomenis Thanos, MD	4:21 PM
		3	Long-Term 10-Year Results After the Inverted ILM Flap Technique for Full-Thickness Macular Holes	Zofia Anna A Nawrocka (vel Michalewska), MD, PhD	4:24 PM
		15	Discussion		4:27 PM
4:42 PM	5:12 PM	30	Macular Pucker - Epiretinal Membrane & Macular Holes Symposium 2		
		3	OCT-Angiography (OCTA)-Guided Single-Day Intense Prone Positioning in Macular Hole Surgery	Subhendu Boral, MBBS, MD(AIIMS), DNB	4:42 PM
		3	Closure Patterns in Macular Holes With Epiretinal Membranes and Correlation With Surgical Technique	Raja Rami P Reddy, MD FRCS FASRS	4:45 PM
		3	5-Year Functional and Anatomical Outcomes in Eyes With Idiopathic Epiretinal Membranes Following Surgical 3 Removal	Lihteh Wu, MD	4:48 PM
		3	Hyperacute Epiretinal Membranes After Retinal Detachment Repair: Anatomic Characteristics, Onset, 3 Progression, and Surgical Timing	Vivek Chaturvedi, MD, FASRS	4:51 PM
		3	Management of Retinal Detachment With Coexisting Macular Hole (MHRD) in the Adult Age Group: 3 Functional and Anatomical Outcome	Pramod S Bhende, MS	4:54 PM
		15	Discussion		4:57 PM
5:12 PM	5:33 PM	21	Panel discussion on POD Presentations: Themes by Topics		5:12 PM
5:33 PM	6:33 PM	60	Scientific Poster Q&A and Exhibit Hall Reception		5:33 PM
			Friday, August 1		
6:45 AM	7:45 AM		Experience Lab (Fellows & Residents)		
6:45 AM	7:45 AM		International breakfast with presentations		
8:00 AM	8:35 AM	35	Surgical Techniques Symposium 1		
		3	Comparison of Traction Force between Current Generation and Next Generation Vitrectomy Systems (25Ga)__PRESENT	Steve T Charles, MD FASRS FACS FICS	8:00 AM
		3	Functional Assessment of a Novel 27-Gauge Multi-Spot Laser Probe in a Surgical Simulation Bioniko Eye 3 Model	Kourous A Rezaei, MD	8:03 AM

			The Safety, Brightness and Clinical Options of the LED RGB Light Source on the UNITY Vitreoretinal Cataract System (VCS) Platform	David R Chow, MD, FRCS(C)	8:06 AM
		8	Discussion		8:09 AM
		3	Volumetric Evaluation of Novel Single-Step Subretinal Injection Device Using Microscope-Integrated Optical Coherence Tomography	Lejla Vajzovic, MD, FASRS	8:17 AM
		3	Secondary Scleral-Sutured Toric Intraocular Lens for Astigmatic Correction in the Absence of Capsular Support	Matthew Starr, MD	8:20 AM
		3	Eight year Outcomes of Pars Plana Vitrectomy and Scleral-Fixated Intraocular Lens Using Gore-Tex Sutures	Luis A Acaba-Berrocal, MD	8:23 AM
		9	Discussion		8:26 AM
8:35 AM	9:15 AM	40	Surgical Techniques Symposium 2		
		3	Postoperative Day 0 as a Substitute for Postoperative Day 1 Examination Following Vitreoretinal Surgery: A Comparative Prospective Study	Christina Y Weng, MD, MBA, FASRS	8:35 AM
		3	Drop less Vitrectomy with 'Suprachoroidal Trimoxil': A Comparative Analysis of Safety and Efficacy with standard of care topical drops	K. V Chalam, MD, PhD, MBA, FRCS(C), FASRS	8:38 AM
		3	A Prospective Assessment of the ASRS Surgical Log as a Tool to Accurately Assess Fellow Role and Performance in Surgery	Alexander Melamud, MD, MA	8:41 AM
		9	Discussion		8:44 AM
		3	Combined Vitrectomy and Reduced-Dose Transscleral Diode Laser Cyclopexy for Managing Large Cyclodialysis Clefts: A Vitreoretinal Approach	Mauricio Bayram-Suverza, MD	8:53 AM
		3	Modified Simple Silicone Materials in T-Shaped Macular Buckling Surgery	Yodpong Chantarasorn, MD	8:56 AM
		3	Visual Outcomes After 1-Stage vs 2-Stage Surgery for Intraocular Foreign Body Removal and Open-Globe Repair, Multicenter Study	Jinghua Chen, MD, PhD	8:59 AM
		3	Low-Dose Atropine 0.01% Drops for Symptomatic Vitreous Floaters: A Noninvasive, Safe, and Effective Therapeutic Option	Mohsin H Ali, MD	9:02 AM
		10	Discussion		9:05 AM
9:15 AM	9:50 AM	35	Surgical Complications Symposium		
		3	Early Vitrectomy vs Intravitreal Antibiotics Only for Postinjection Endophthalmitis: An IRIS (Intelligent Research in Sight) Registry Report	Andrew C Lin, MD	9:15 AM
		3	Cataract Surgery Complications in Individuals Who Previously Received Intravitreal Injections	Peter J Kertes, MD, FRCS(C)	9:18 AM
		3	The Impact of Prefilled Syringe Technology on Rates of Endophthalmitis Following Intravitreal Injection of Faricimab	Philip P Storey, MD, MPH	9:21 AM
		3	Diagnostic Yield of Diluted Aqueous Fluid Analyzed With Polymerase Chain Reaction Testing in the Workup of Infectious Uveitis	Mariam Mathai, MD	9:24 AM
		3	Long-Term Visual and Surgical Outcomes in 33 Eyes With Noninfectious Uveitis Requiring Secondary Lens Implantation	Sruthi Arepalli, MD	9:27 AM
Fellows Forum Award Winner		3	Retinal Complications After Cataract Surgery for Adult Patients With a History of Retinopathy of Prematurity: An IRIS (Intelligent Research in Sight) Registry Analysis	Nikhil Bommakanti, MD	9:30 AM
		17	Discussion		9:33 AM
9:50 AM	10:30 AM	40	Break		
10:30 AM	11:00 AM	30	Wet AMD Symposium 1		
		3	Baseline and Early Treatment Response Variables Associated With Faricimab Durability in Treatment-Naive nAMD: TENAYA/LUCERNE Post Hoc Analyses	Benjamin Bakall, MD, PhD	10:30 AM
		3	Rapid Fluid Resolution With Aflibercept 8 mg May Be Associated With Extended Dosing Intervals at Week 96 in nAMD: A PULSAR Post Hoc Analysis	Michael W Stewart, MD	10:33 AM
		3	PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration	David T Wong, MD, FRCS(C), DRCPSC, FASRS	10:36 AM
		3	Indirect Comparison of the Relative Effectiveness of Faricimab vs Aflibercept 8 mg in DME and nAMD	Nikolas J London, MD, FACS, FASRS	10:39 AM
		3	5-Year Outcomes in nAMD Patients Enrolled in the Archway Study and Treated With the PDS	John W Kitchens, MD	10:42 AM
		15	Discussion		10:45 AM
11:00 AM	11:45 AM	45	Wet AMD Symposium 2		
		3	Treatment Burden in Wet Age-related Macular Degeneration Treated with EYP-1901 Versus Aflibercept in the DAVIO 2 Phase 2 Clinical Trial	Avni P Finn, MD, MBA, FASRS	11:00 AM

			3 Vision Outcomes From the DAVIO 2 Trial: A Phase 2 Trial of EYP-1901 vs Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration	Jennifer I Lim, MD, FARVO, FASRS	11:03 AM
			3 COAST: A Phase 3 study of intravitreal sozinibercept combined with aflibercept in participants with neovascular age-related macular degeneration	Charles C Wykoff, MD, PhD, FASRS	11:06 AM
			3 PRISM Phase 2b Clinical Trial Evaluating Intravitreal 4D-150 in Adults With Neovascular Age-Related Macular Degeneration: 52-Week Results	John A Wells, MD, FACS	11:09 AM
			3 Vials vs Prefilled Syringes (PFS): Intraocular Pressure (IOP) Spikes From 151,657 Intravitreal Injections (IVIs) From 2010 to 2025 From a Single Center in the United Kingdom	Ian YL Yeung, MA FRCOphth	11:12 AM
			3 Real-World Intraocular Pressure (IOP) and Glaucoma Outcomes From Intravitreal Treatments Based on Injection Volume	Deepak Sambhara, MD	11:15 AM
			3 Acute Optic Nerve Anatomic Changes Following Intravitreal Injection of Pharmaceutical Agents	Sami H Uwaydat, MD	11:18 AM
			3 Swing vs Flick: Assessing Safer Air Bubble Removal Techniques in Intravitreal Injections	Gustavo B Melo, MD, PhD, FASRS	11:21 AM
		21	Discussion		11:24 AM
11:45 AM	12:15 PM	30	Wet AMD Symposium 3		
			3 1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD	Robert L Avery, MD	11:45 AM
			3 RO-104, a Novel Trispecific Antibody, Significantly Reduces Lesion Area and Vascular Leakage in a Laser-Induced Nonhuman Primate CNV Model	Harit K Bhatt, MD, MBA, FASRS, FACS	11:48 AM
			3 Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD): Results From OPTIC and LUNA Trials	Sean D Adrean, MD, FAAO, FASRS	11:51 AM
			3 Longitudinal Validation of the Performance of an AI-Based Algorithm in a Home OCT Pivotal Study of Age-Related Macular Degeneration	S. Krishna Mukkamala, MD, FASRS	11:54 AM
			3 The Effect of Baseline Ellipsoid Zone-Area Loss on Treatment Response of Revakinagene Taroretcel (NT-501) in Macular Telangiectasia Type 2	Sophie J Bakri, MD	11:57 AM
		15	Discussion		12:00 PM
12:15 PM	12:36 PM	21	Case-Based Panel Discussion: Wet AMD	Christina Y Weng, MD, MBA, FASRS	12:15 PM
12:36 PM	1:07 PM	31	Awards Ceremony		
		2	Pyron Award Introduction	Gaurav K. Shah, MD	12:36 PM
		5	Illuminating the Unknown: Advancing Retinal Science to Restore Vision	Rajendra S Apte, MD, PhD	12:38 PM
		2	Founders Award Introduction	J Michael Jumper, MD, FASRS	12:43 PM
		5	The Beauty of Inverted ILM Flap	Jerzy Nawrocki, MD, PhD	12:45 PM
		2	Young Investigators Award Introduction	Reginald J Sanders, MD	12:50 PM
		5	“Novel Insights and Future Directions in Rhegmatogenous Retinal Detachment”	Rajeev H Muni, MD, MSC, FRCS(C), FASRS	12:52 PM
		2	Packo Award Presentation to Kevin J. Blinder, MD, FASRS	J Michael Jumper, MD, FASRS	12:57 PM
		2	Crystle Apple Award Presentation to Sunil Srivastava, MD	ECS co-Chairs	12:59 PM
		1	Retina Image Bank Image of the Year	Reginald J Sanders, MD	1:01 PM
		1	Retina Atlas Chapter of the Year	Retina Altas Editors	1:02 PM
		2	2025 M. Gilbert Grand ASRS Vitreoretinal Fellowship Award to Jonathan B Lin, MD, PhD	Reginald J Sanders, MD	1:03 PM
		2	Retina Hall of Fame Award	John T Thompson, MD	1:05 PM
1:07 PM	2:22 PM	75	General Lunch + Early Career Section Lunch		
2:22 PM	2:32 PM	10	Invited Talk: How to Manage Nevi Day to Day for the Vitreoretinal Surgeon	Amy C Scheffler, MD FACS FASRS	
2:32 PM	3:07 PM	35	Ocular Oncology Symposium		
			3 Gene Expression Profiling Accurately Predicts Mortality for Medium and Large Uveal Melanoma: Improved Survival Outcomes for Class 1a Greater Than Class 1b Greater Than Class 2	Timothy G Murray, MD, MBA, FASRS	2:32 PM
			3 Detection of Germline BAP1 Mutations in Patients With Uveal Melanoma	Amy C Scheffler, MD FACS FASRS	2:35 PM
			3 Independent Validation of a 16-Protein Test to Assess Malignant Potential of Small Uveal Melanocytic Tumors	David A Reichstein, MD	2:38 PM
		8	Discussion		2:41 PM
			3 Racial and Ethnic Disparities in Retinoblastoma Treatment Options: A Multi-institutional TriNetX Analysis	Vivienne S Hau, MD, PhD	2:49 PM
			3 Endodiode Laser With Vitrectomy-Transretinal Biopsy (EDL-VitBx) for Treatment of T1 and T2 Uveal Melanoma: Initial Results of Vision-Sparing, Definitive Local Therapy	Scott C Oliver, MD	2:52 PM
			3 Retinal Pigment Epithelium Undulations in Primary Vitreoretinal Lymphoma: Hidden Paradox	VISHAL R RAVAL, MBBS, DNB, FMRF, FASRS	2:55 PM
		9	Discussion		2:58 PM
3:07 PM	3:28 PM	21	Case-Based Panel Discussion: Ocular Oncology	Timothy G. Murray, MD, FASRS	
3:28 PM	4:08 PM	40	Break		

4:08 PM	4:18 PM	10	Invited Talk: Genetic Testing for the Retina Specialist: What You Need to Know	Aaron Nagiel, MD, PhD	
4:18 PM	4:53 PM	35	Hereditary Retinal Disease & Genetics Symposium 1		
		3	Retinal Gene Therapy Surgical Techniques	Robert E MacLaren, DSc DPhil FRCS FRCOphth FACS FMedSci	4:18 PM
		3	Subretinal Laru-zova Gene Therapy for XLRP: 24-Month Results of the Randomized, Controlled, Multicenter Phase 2 SKYLINE Trial	Robert A Sisk, MD, FACS, FASRS	4:21 PM
		3	A Novel Modifier Gene Therapy for Retinitis Pigmentosa: 2-Year Results of a Phase 1/2, Multicenter, Dose-Escalation Study of Subretinal OCU400	Syed Shah, MD	4:24 PM
		8	Discussion		4:27 PM
		3	Extended Efficacy and Safety of MCO-010 Optogenetic Therapy for RP: 126-Week Results From the RESTORE Follow-Up Study (REMAIN)	David S Liao, MD, PhD	4:35 PM
		3	Oral Gildeuretinol Slows Disease Progression in Early Stargardt Disease: Updates From the TEASE-3 Study	Kenneth C Fan, MD, MBA	4:38 PM
		3	Secretion of Ciliary Neurotrophic Factor by NT-501 Encapsulated Cell Technology in Patients With Retinal Degenerative Disorders	Jiong Yan, MD	4:41 PM
		9	Discussion		4:44 PM
4:53 PM	5:13 PM	20	Hereditary Retinal Disease & Genetics Symposium 2		
		3	Key Determinants Influencing Molecular Confirmation After Genetic Testing for Inherited Retinal Dystrophies	Joao Pedro Marques, MD, MSc, PhD, FEBOphth	4:53 PM
		3	Peripheral Retinal Vessels in Retinitis Pigmentosa	Hossein Ameri, MD, PhD, FRCOI, MRCOphth	4:56 PM
		3	North Carolina Macular Dystrophy: Haplotype Analysis of 31 Families Shows Single Founders for Each Mutation	Kent W Small, MD, FASRS, FACS	4:59 PM
		3	Comparison of Retinal Layer Thicknesses After Macular Hole Surgery and Alport Syndrome	Gursel Yilmaz, MD, FEBO, FACS, FASRS	5:02 PM
		8	Discussion		5:05 PM
5:13 PM	5:31 PM	18	Pediatric Retina - ROP Symposium		
		3	P-Score Variability in Retinopathy of Prematurity as a Function of Image View, Capture Time, and Disease Severity	Darius M Moshfeghi, MD, FASRS	5:13 PM
		3	Evaluating Clinical Signs of Regression in Eyes Treated With Intravitreal Bevacizumab for Type 1 Retinopathy of Prematurity	Yuxi Zheng, MD	5:16 PM
		3	Familial Exudative Vitreoretinopathy (FEVR): Genotype-Phenotype Associations and Microvascular Abnormalities on Optical Coherence Tomography (OCTA)	Audina M Berrocal, MD FASRS	5:19 PM
		9	Discussion		5:22 PM
5:31 PM	7:16 PM	105	WinR Case Conference		
			Saturday, August 2		
6:45 AM	7:45 AM		Experience Lab (Fellows & Residents)		
6:45 AM	7:45 AM		DEI Breakfast		
6:45 AM	7:45 AM		OMIC symposium		
8:00 AM	8:35 AM	35	Practice Management & Socioeconomics Symposium		
		3	Accuracy of Initial Anti-VEGF Treatment Selection in Newly Diagnosed Neovascular Age-Related Macular Degeneration: Retina Specialist Choice vs Step Therapy	Prithvi R Bomdica, MD, MBA	8:00 AM
		3	Economic Impact of Anti-Vascular Endothelial Growth Factor Prior Authorization Process	Ella H Leung, MD	8:03 AM
		3	Retinal Procedure Volume and Inflation-Adjusted Medicare Reimbursement in the 21st Century	Ron A Adelman, MD, MPH, MBA	8:06 AM
		8	Discussion		8:09 AM
		3	Analysis of Antivascular Endothelial Growth Factor Utilization Trends and Prescriber Characteristics Based on Medicare Part B Claims Data: 2017-2022	Stephanie B Engelhard, MD	8:17 AM
		3	Comparative Cost Analysis of Secondary Intraocular Lens Surgeries Using Time-Driven, Activity-Based Costing	Warren W Pan, MD, PhD	8:20 AM
		3	Take Out the Trash: Environmental Burden Associated With Intravitreal Injections	Abdullah Abou-Samra, MD	8:23 AM
		9	Discussion		8:26 AM
8:35 AM	8:45 AM	10	Invited Talk: Amniotic Membrane in Vitreoretinal Surgery: When and How	Stanislao Rizzo, MD	8:35 AM
8:45 AM	9:25 AM	40	Retinal Detachment Symposium 3		
		3	Primary Retinal Detachment Repair in Eyes Deemed High Risk for Proliferative Vitreoretinopathy: Surgical Outcomes in 605 Eyes	M. Ali Khan, MD, FACS, FASRS	8:45 AM
		3	Interim Report of the FIXER Trial: Prevention of Proliferative Vitreoretinopathy With Intravitreal Methotrexate in Primary Retinal Detachment Repair	Christopher D Riemann, MD	8:48 AM

			Intravitreal Methotrexate for the Treatment and Prevention of Proliferative Vitreoretinopathy in Pediatric Patients	Philip J Ferrone, MD, FASRS	8:51 AM
		9	Discussion		8:54 AM
		3	Hypotony Rates After Vitrectomy for PVR: Insights on Intravitreal MTX Use	Mostafa Mafi, MD	9:03 AM
			Encircage and External Drainage to Enhance Vitrectomy Outcomes in Chronic Rhegmatogenous Retinal Detachment with Extensive PVR: A Retrospective Study	Jayant Dr Kumar, MBBS, MS, DNB, MNAMS, FICO, FVRS	9:06 AM
		3	From Bench to Bedside: Investigating the Use of Netarsudil as a Novel Therapeutic Approach for PVR	Leo A Kim, MD, PhD	9:09 AM
			Postoperative Methotrexate Injections Decrease Reoperation Rate and Improve Vision Following Vitrectomy for PDR and Complex Retinal Detachments	Alan J Franklin, MD, PhD, FASRS	9:12 AM
		10	Discussion		9:15 AM
9:25 AM	10:05 AM	40	Retinal Detachment Symposium 4		
			Anatomical and Functional Outcomes of Vitrectomy for the Management of Longstanding Closed Funnel Retinal Detachments: A Single-Center Study	Malek Yassine, MD	9:25 AM
		3	Assessment of Redetachment Based on Proliferative Vitreoretinopathy Findings on SS-OCT	Isabela Martins Melo, MD	9:28 AM
			Association of Serum Vitamin D Insufficiency With Proliferative Vitreoretinopathy After Rhegmatogenous Retinal Detachment Repair	Steven D Ness, MD	9:31 AM
			Novel Technique of Perfluoro-n-Octane (PFO): Guided Retinectomy Improves Single-Surgery Anatomic Success (SSAS) in Eyes With Proliferative Vitreoretinopathy (PVR)	Ajay E Kuriyan, MD, MS	9:34 AM
			Comparative Cost Analysis of Pediatric and Adult Retinal Detachment Repairs Using Time-Driven, Activity-Based Costing	Nita Valikodath, MD, MS	9:37 AM
		3	Learning Curve of Scleral Buckling Surgery: The Journey of a Retina Fellow's First 100 Surgeries	Pallavi Priya, MS	9:40 AM
			The Reservoir Technique for Silicone Oil Placement: Intraocular Pressure Control and Long-Term Outcomes	Kathleen R Schildroth, MD	9:43 AM
		3			9:43 AM
		19	Discussion		9:46 AM
10:05 AM	10:15 AM	10	Invited Talk: OCT Miomarkers for Surgical Retinal Disorders	Srinivas R Sadda, MD	10:05 AM
10:15 AM	10:55 AM	40	Break		10:15 AM
10:55 AM	11:10 AM	15	Best of JVRD Panel	Timothy G Murray, MD, MBA, FASRS	10:55 AM
11:10 AM	11:40 AM	30	Dry AMD Symposium 3		
			Safety and Efficacy of OCU410, a Novel Modifier Gene Therapy, for Treatment of Geographic Atrophy: Phase 1/2 Study Update	Jay Chhablani,	11:10 AM
			Changes in Hyperautofluorescence Area and RPE/Outer Retinal Layer Thickness in the Phase 2a SIGLEC Study Assessing AVD-104 for the Treatment of GA	Carl D Regillo, MD	11:13 AM
		3	Safety, Tolerability, and Properties of Novel C3 Inhibitor BI-C in Patients With Geographic Atrophy	Brian B Berger, MD	11:16 AM
			Deactivation of CD163+ Retinal Macrophages With AVD-104 Siglec Agonism Can Restore Photoreceptor Function and Vision in Geographic Atrophy	Eleonora M. Lad, MD, PhD	11:19 AM
		3	Biomarker-Based Efficacy Analysis of Intravitreal CFH Supplementation in a Phase 2 Trial	David M Brown, MD	11:22 AM
		15	Discussion		11:25 AM
11:40 AM	12:10 PM	30	Dry AMD Symposium 4		
		3	A 'Digital Twin' Approach to Modeling Geographic Atrophy Growth	Naresh Mandava, MD	11:40 AM
			Delayed Near-Infrared Analysis (DNIRA) Identifies Novel and Changing Features of Nonexudative (Dry) Age-Related Macular Degeneration (AMD): A Longitudinal Study	Shelley R Boyd, MD, FRCS(C)	11:43 AM
		3	Vessel density changes in choroid, chorioacapillaries, deep and superficial retinal plexues on OCTA in various stages of ARMD	Prashant K Bawankule, M.S.	11:46 AM
			Retro-Mode (RM): A Newer Insight Into Dry Age-Related Macular Degeneration	SHILPI H NARNAWARE, ICO (Retina) , FAICO (Vitreo-Retina)	11:49 AM
		3	Elamipretide Protection Against Photoreceptor Loss in Dry AMD: Predictive Baseline Quantitative Ellipsoid Zone Integrity Parameters in ReCLAIM-2	David R. Lally, MD	11:52 AM
		15	Discussion		11:55 AM
12:10 PM	12:20 PM	10	PAT Survey and Global Trends Panel		12:10 PM
12:20 PM	1:35 PM	75	General Lunch + BOR Lunch		12:20 PM
1:35 PM	1:45 PM	10	Creative Awards		1:35 PM
1:45 PM	2:25 PM	40	Diabetic Retinopathy Symposium 3		
			Outcomes of Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States Who Were Lost to Follow-up	Rahul N Khurana, MD, FASRS	1:45 PM
		3	Incidence of Sight-Threatening Pathology Detected by Non-Mydriatic Fundus Photography in a National Diabetic Screening Platform	Shawn C Kavoussi, MD	1:48 PM

			Lower Socioeconomic Status Is Associated With Increased Bevacizumab Use Among Patients Initiating Anti-VEGF Therapy for Diabetic Macular Edema	Judy E Kim, MD, FARVO, FASRS	1:51 PM
			Neighborhood-Level Characteristics Associated With Delay in Surgery and Loss to Follow-up in Tractional Retinal Detachment Due to Proliferative Diabetic Retinopathy	Sally S Ong, MD	1:54 PM
			Diagnosis of Chronic Kidney Disease Using Retinal Imaging and Urine Dipstick Data: A Multimodal Deep Learning Approach	Joonhyung Kim, MD, PhD	1:57 PM
			ChatGPT for Diabetic Retinopathy Screening	Saeed Mohammadi, MD	2:00 PM
			Systemic Biomarkers and Retinal Microvascular Alterations as Noninvasive Indicators of Diabetic Retinopathy and Nephropathy Severity and Diagnosis	Kasra Rezaei, MD	2:03 PM
		19	Discussion		2:06 PM
2:25 PM	3:05 PM	40	Diabetic Retinopathy Symposium 4		
			The Association of Pars Plana Vitrectomy With the Progression From Nonproliferative to Proliferative Diabetic Retinopathy	Ahmed B Sallam, MD PhD FRCOphth	2:25 PM
		3	Mortality Rates Following Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy	Karen M Wai, MD	2:28 PM
		3	The Risk of Hypoglycemia in Diabetes: An Outcomes-Based Analysis	Shree K Kurup, MD	2:31 PM
		3	Risk Factors for Diabetic Retinopathy Progression During Pregnancy	Majda Hadziahmetovic, MD	2:34 PM
			Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide	Andrew J Barkmeier, MD	2:37 PM
			Reduced Rates of Diabetic Retinopathy Complications With Use of Continuous Glucose Monitoring: A Multicenter Population-Based Study	Ehsan Rahimy, MD	2:40 PM
		3	Peripheral Visual Fields in Severe Nonproliferative Diabetic Retinopathy	Jun Kong, MD, PhD	2:43 PM
		19	Discussion		2:46 PM
3:05 PM	3:40 PM	35	Retinal Vascular Disease Symposium 1		
			Timing of Ocular Adverse Events in Pooled Analysis of Two Phase 3 Trials of Revakinagene Taroretcel (NT-501) in Macular Telangiectasia Type 2	Dean Elliott, MD	3:05 PM
		3	A Telemedicine-Enabled Intravenous Thrombolytic Treatment Pathway for Patients With Hyperacute Nonarteritic Central Retinal Artery Occlusion	Robin A Vora, MD	3:08 PM
			Visual Recovery in Patients With Central Retinal Artery Occlusions Treated With Intravenous Thrombolysis	Boback S Modjtahedi, MD	3:11 PM
		3	The Impact of Glucagon-Like Peptide-1 Receptor Agonists on the Risk of Retinal Vein and Artery Occlusions	Aleksandra V Rachitskaya, MD, FASRS	3:14 PM
			Identification of Risk Factors Associated With Development or Progression of Proliferative Sickle Cell Retinopathy	Adrienne W Scott, MD, FASRS	3:17 PM
		3	Surgical Outcomes for Proliferative Sickle Cell Retinopathy	Hesham Gabr, MD	3:20 PM
		17	Discussion		3:23 PM
3:40 PM	4:10 PM	30	Retinal Vascular Disease 2		
			From Bench to Bedside in CSCR: Discovery of a Rare Genetic Risk Variant and Correlation With In-Human Data Using Faricimab	Elizabeth Rossin, MD, PhD	3:40 PM
			Associations Between Androgen Exposure, PCOS, and Transmasculine Individuals With Central Serous Chorioretinopathy	Danny A Mammo, MD	3:43 PM
			Aflibercept 8 mg in Treatment-Naive Macular Edema Secondary to Retinal Vein Occlusion: Primary Endpoint Results From the QUASAR Study	Seenu M Hariprasad, MD	3:46 PM
			Intracameral Delivery of Bevacizumab in the Management of Anterior Segment Recalcitrant Neovascular Complications of Proliferative Vascular Retinopathies	Marib I Akanda, MD	3:49 PM
		3	First In-Human Study Using a Novel Suprachoroidal Injector	Yoreh Barak, MD	3:52 PM
		15	Discussion		3:55 PM
4:10 PM	4:31 PM	21	Case-Based Discussion: Retinal Vascular Disease	Diana V. Do, MD, FASRS	4:10 PM
7:00 PM	11:59 PM		Closing Reception: The Queen Mary		